Ipilimumab — CTLA-4 Immune Checkpoint Inhibitor in Cancer Treatment
July 06, 2026
Ipilimumab inhibits CTLA-4, amplifying the anti-cancer immune response. Commonly combined with Nivolumab for optimal outcomes.
CTLA-4 Inhibition Mechanism
Ipilimumab is a monoclonal antibody targeting CTLA-4 — a regulatory "brake" receptor on T cells. By blocking CTLA-4, Ipilimumab enhances and prolongs anti-tumour T cell activity. It was the first approved immune checkpoint inhibitor for melanoma.
Combination with Nivolumab
The Ipilimumab + Nivolumab combination (doublet immunotherapy) is now standard in advanced melanoma, high PD-L1 lung cancer, renal cell carcinoma and hepatocellular carcinoma. Response rates exceed monotherapy but immune-related adverse events also increase — close monitoring is required.
In China
Ipilimumab + Nivolumab doublet immunotherapy is applied at HYGEIA and GoBroad for advanced melanoma, lung and renal cancer.
Disclaimer
Information is for reference only. The physician determines the protocol and manages adverse events.
Related Images
